News Room

Plexus Ventures Selected by a Major Multinational Company for Divestment of OTC Products

January 27, 2017

Philadelphia, Pennsylvania – A major multinational company has appointed Plexus Ventures, a global pharmaceutical consulting firm, to assist with the divestment of some of their mature OTC Products in Europe and other territories.

Plexus Ventures will run a divestment process with the twofold objective of (1) maximizing the proceeds and (2) selecting one or more parties who can commit to a smooth transaction and an efficient transition phase.

About Plexus Ventures

Now in its 27th year, Plexus Ventures provides strategic advice, business development and alliance management services to clients in the pharmaceutical, consumer healthcare and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Barcelona, Basel, Beijing, Indianapolis, London, Los Angeles, Milan, Oxford, Philadelphia, Sao Paulo and Tokyo, Plexus Ventures possesses the capabilities to effectively serve clients in North America, South America, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.